Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 4.25 4.00 4.50 4.50 4.25 4.25 389,627 14:37:54
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.1 -2.7 - 6

Evgen Pharma Share Discussion Threads

Showing 1551 to 1575 of 1900 messages
Chat Pages: Latest  64  63  62  61  60  59  58  57  56  55  54  53  Older
DateSubjectAuthorDiscuss
23/9/2019
07:05
So I made my goal of being the longest on this drug, so far, I’m ecstatic and pleased for all the others who have had success and are still continuing,one of the main bonus,s for me has been the mild side effects, my quality of life is very good. My hubby pointed out that maybe my diet choices over this time have helped also,I still continue to eat lots of broccoli and greens and a good diet, with a few naughty bits thrown in to keep me on track, who knows with this disease. Anyway here’s to another 6 weeks progression free till next scan.😀ԅ12;
blakeysangel
23/9/2019
06:29
Excellent news. Presentation in Barcelona 29.09.19.
snowyflake
23/9/2019
06:18
Excellent news. For success in the next trial they are hoping for 8 months of PFS. To have 5 people demonstrate success for over 12 months most be encouraging. And as the news release states you would hope for even better results when given at an earlier stage. I wonder why they released this news now. Perhaps to share with potential partners.
pdt
23/9/2019
06:13
Brilliant result in that RNS
dave444
20/9/2019
09:57
Hello again, There’s a poster on LSE called Greg25 who seems really clued-up about Evgen. Does he post on here? Thanks
pennyfalls
19/9/2019
18:53
Ps Looks like my weird tick-down troll from NFX is following me around again! (Unless it was just a deservedly bad first post!)
pennyfalls
19/9/2019
11:39
Morning all... Just bought in here this morning. Looks very promising indeed. I’ve been reading about this for last 3 days, including Blakeysangel’s kind input - and I hope things go well for you. Very heartwarming. I love how this drug has potential not only in Cranium bleeds, but autism, cognitive function in mental illness and obviously cancer. Potent thing those Broccoli phytochemicals :o) The chart is looking primed for a breakout and news (in next few weeks) will probably be catalyst, although it may nudge up before then. Gap in chart today to be filled circa 16.15- 16.20 ish. Thanks everyone for an informative and level-headed board, and please share more info. Thanks and good luck, PF
pennyfalls
12/9/2019
21:06
Blakeysangel - thanks for keeping us informed and hopefully SFX-01 will keep working for you for a long time to come. Enjoy the seaside, incidently I live on the coast looking out over water and love it.
pdt
12/9/2019
20:33
Thanks everyone for your support. It’s interesting ,PDT ,that the next trial is at a earlier stage, 2nd line treatment after CDK4/6, I’m yet to have a CDK4/6 as I’m on tamoxifen so perhaps if things do progress I maybe able to drop on a trial again with STEM in partnership with a different treatment. PDT I’ve been on the trial since early June 2018 and won’t be scanned again till November at the earliest.Till then the seaside and enjoying early retirement is what I’ll be doing 😀😀.
blakeysangel
12/9/2019
13:17
diamondstar1 - in these cases they are trying to increase rather than inhibit NRF2. SFX-01 is sulforaphane based and one of the unique properties is that it crosses the blood brain barrier and being in the SFX-01 formulation it is stable and suitable for clinical studies. There were some studies into the analogues and SFX-01 was the most potent NRF2 activator for use in SAH. There are other companies with NRF2 activators such as Reata Pharma (US) and C4X (UK) has an early stage molecule. There are some links on Evgen's website re action of SFX-01 and Multiple Sclerosis.
pdt
12/9/2019
12:06
Thanks PDT - you are perfectly right. There was an announcement on 28-Aug-2019, that the last patient had achieved final study visit. Add 6 weeks to this - and the results could be released as early as mid October, or possibly late Oct as you suggest. PDT - do you understand the key differences between NRF2 inhibition with SFX-01 and other NRF2 inhibitors e.g. Biogen’s marketed product for relapsing-remitting multiple sclerosis?
diamondstar1
12/9/2019
11:50
diamondstar1 - the company announced that the last data was collected end of August and that results would be Q4. I suspect end of October. A good article worth a read is; Neuroprotective Role of the Nrf2 Pathway in Subarachnoid Haemorrhage and Its Therapeutic Potential hTTps://www.hindawi.com/journals/omcl/2019/6218239/
pdt
12/9/2019
11:31
Hi there, I’m totally new to this Evgen blog. Have not invested as yet, but I am potentially interested. Firstly, the question I’m asking is when the results of the Ph2 trial will be released? Quick check on clinicaltrials.gov shows that the study sites are active, but have stopped recruiting. Thus, the study has completed recruiting the last patient in early Sept as my guess. Since the patients are dosed on SFX-01 300mg twice daily for 4 weeks, and followed up for Primary Endpoints for a total of 4 weeks, the estimated study completion date should be end-Sept, or perhaps early October. Once study is completed, there will be intensive activity in collecting all relevant clinical trial data, quality checking the data, and producing tables and listings. This activity towards database lock usually takes 4-6 weeks and should span across the whole of October, possibly the first half of November. Hence, my target date for disclosure of the Ph2 SAH results would be mid November. It looks to me like we are about 2 months away from finding out the Ph2 results. Interesting times ahead!
diamondstar1
12/9/2019
09:46
Blakeysangel - setting aside one's commercial hopes for SFX-01, I and am I sure others wish you all the very best.
snowyflake
12/9/2019
09:25
Blakeysangel - it is great to hear your news! It is also encouraging for the prospects of the next trial. To be viewed as a success they are looking for about 8 months of PFS. I think Blakeysangel must be on about 15 months and when the trial results were announced there was someone on 14 months. And some 13 people on the compassionate use programme of 6 months plus duration. I believe the company hopes for even better results overall from the new trial since it will be positioned, at an earlier stage, as a second line treatment after CDK4/6. Combined with excellent safety and low side effects I would have thought that a partner may be interested in this next trial. More information should be disclosed at the Barcelona event at the end of this month. Exciting times for Evgen especially with the SAH results also due in Q4.
pdt
11/9/2019
14:52
Your positive attitude is infectious!
nobbygnome
11/9/2019
14:15
Hi Nobby, Just nausea but the that wears off after a couple of hours, I’m tired but that could be my other meds. I have a good quality of life which is what it’s about..just off to the seaside so alls good 😀😀
blakeysangel
11/9/2019
14:01
Hi Nobby, Just nausea but the that wears off after a couple of hours, I’m tired but that could be my other meds. I have a good quality of life which is what it’s about..just off to the seaside so alls good 😀😀
blakeysangel
11/9/2019
12:46
Good news! Do you have any discernible side effects from SFX01?
nobbygnome
11/9/2019
12:42
Hi, Onco appointment done today and continuing on Stem SFX01 for at least another 2 months till next scan... feeling happy!! Just need the Share price rise! 😀😀😀
blakeysangel
06/9/2019
18:35
I am a new shareholder as of yesterday and have read the latest year's accounts. The last two placings have each been at higher prices - somewhat unusual one may think - that shows confidence in the company and what the directors are trying to achieve on the part of the placees. The directors say that the company, on current estimates, is funded until after 2020; note after 2020. Like solicitors and other professionals, not all doctors are honest but I personally rate these directors. The SFX-01 clinical trial results should be released in Q4 2019- i.e. anytime from and including this October until the end of December but I guess pre- Christmas as the backstop (that hateful word!!). Also, the directors, unlike those of so many junior companies, are not taking inordinate salaries and treating the company as their thiefdom - so often causing a company to be attacked by the rogue bloggers and thus destroying share value. The stock could have an upward move soon.
snowyflake
06/9/2019
18:19
Due a move upwards
shares188
05/9/2019
09:09
I agree - clearly very interesting news and fascinating too. I am looking forward to seeing where this ends up in the years ahead.
lovewinshatelosses
05/9/2019
08:26
Today's news release is impressive. SFX-01 could prove of use beyond assisting autistic youngsters - say MS and other neurological problems.
snowyflake
29/8/2019
05:58
It was a nothing RNS. So the last patient last visit happened; I am not sure that is worth RNSing. I guess we know that patient at least survived through to the end, although of course mortality is not a primary end point!
nobbygnome
Chat Pages: Latest  64  63  62  61  60  59  58  57  56  55  54  53  Older
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200229 07:21:52